DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Carmen Hidalgo-TenorioJuan PasquauDavid VinuesaSergio FerraAlberto TerrónIsabel SanJoaquínAntoni PayerasOnofre Juan MartínezMiguel Ángel López-RuzMohamed OmarJavier de la Torre-LimaAna López-LirolaJesús PalomaresJosé-Ramon BlancoMarta Montero-AlonsoCoral García-VallecillosPublished in: Viruses (2022)
Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- hiv infected
- end stage renal disease
- body mass index
- hiv positive
- ejection fraction
- chronic kidney disease
- newly diagnosed
- hiv aids
- prognostic factors
- peritoneal dialysis
- physical activity
- body weight
- hiv testing
- electronic health record
- weight gain
- patient reported outcomes
- machine learning
- south africa
- artificial intelligence
- patient reported